<DOC>
	<DOCNO>NCT02450526</DOCNO>
	<brief_summary>The objective study demonstrate efficacy Dysport improvement appearance moderate severe glabellar line assess short term long term safety Dysport , use improvement appearance moderate severe glabellar line Chinese subject .</brief_summary>
	<brief_title>Dysport Treatment Glabellar Lines Chinese Subjects</brief_title>
	<detailed_description>The first treatment cycle double blind subject randomise receive Dysport , Botox placebo . After first treatment cycle , subject receive maximum four treatment cycle Dysport , occur interval less 84 Days ( 12 week ) treatment cycle , depend upon individual duration response Dysport treatment .</detailed_description>
	<mesh_term>abobotulinumtoxinA</mesh_term>
	<mesh_term>Botulinum Toxins , Type A</mesh_term>
	<mesh_term>onabotulinumtoxinA</mesh_term>
	<mesh_term>incobotulinumtoxinA</mesh_term>
	<criteria>Provision write informed consent Male female Chinese subject 18 65 year age inclusive . Have moderate severe wrinkle vertical glabellar line ( Grade 2 3 ) maximum frown baseline ( Day 1 ) , assess subject use SSA . Have moderate severe ( Grade 2 3 ) vertical glabellar line maximum frown baseline ( Day 1 ) , assess Investigator use ILA . Be Botulinum Toxin ( BTX ) na√Øve receive recent BTXA treatment 1 year prior screen . Have negative pregnancy test Have understand study Any prior surgery affect corrugator supercilii , prior blepharoplasty brow lift , dermal resurfacing , prior cosmetic procedure scar within 36 month . Any prior treatment permanent filler upper face . Any prior treatment nonpermanent dermal filler upper face within past 3 year and/or skin abrasions/resurfacing , photorejuvenation skin/vascular laser intervention within past 12 month . Any planned facial cosmetic surgery procedure study period . Lack capacity frown . Facial condition could affect safety efficacy result . History facial nerve palsy . Marked asymmetry ; ptosis ; excessive dermatochalasis ; deep dermal scarring ; thick sebaceous skin ; photodamage etc . Presence condition could affect safety , conduct outcome study . Any subject psychiatric illness take antidepressant , anxiolytic antipsychotic medication . Pregnant and/or lactate female subject . Female subject childbearing potential willing use contraceptive measure throughout course study . History drug alcohol abuse . Treatment experimental drug device within 30 day prior screen study conduct study . Requirement BTX injection site ( ) disorder glabellar line . Known allergy hypersensitivity BTX . Any medical condition laboratory find central laboratory result . The subject unable and/or unwilling comply fully protocol study . Mental incapacity , unwillingness language barrier .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>